Detectible mosaic truncating PPM1D mutations, age and breast cancer risk

Mitchell J. Machiela, Timothy A. Myers, Christopher J. Lyons, Roelof Koster, William D. Figg, Leandro M. Colli, Lea Jessop, Thomas U. Ahearn, Neal D. Freedman, Montserrat García-Closas, Stephen J. Chanock*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Mosaic protein truncating variants (PTVs) in the phosphatase, Mg2+/Mn2+dependent 1D (PPM1D) gene in blood-derived DNA have been associated with increased risk of breast cancer. We analyzed PPM1D PTVs in blood from 3817 breast cancer cases and 3058 controls by deep sequencing of a previously defined region in exon 6 of PPM1D. We identified 50 of 6875 (0.73%) participants having a mosaic PPM1D PTV. We observed a higher frequency of mosaic PPM1D PTVs with increasing age (Ptrend = 2.9 × 10−6). We did not observe an overall association between PPM1D PTVs and increased breast cancer risk (OR = 1.51, 95% CI = 0.84–2.71). Evidence for an association was observed in a subset of cases with DNA collected 1-year or more before breast cancer diagnosis (OR = 3.44, 95% CI = 1.62–7.30, P-value = 0.001); however, no significant association was observed for the larger series of cases with DNA collected post diagnosis (OR = 1.01, 95% CI = 0.51–2.01, P-value = 0.98). Our study indicates that the PPM1D PTVs are present at higher rates than previously reported and the frequency of PPM1D PTVs increases with age. We observed limited evidence for an association between mosaic PPM1D PTVs and breast cancer risk, suggesting mosaic PPM1D PTVs in the blood likely do not influence risk of breast cancer.

Original languageEnglish
Pages (from-to)545-550
Number of pages6
JournalJournal of Human Genetics
Issue number6
StatePublished - 1 Jun 2019
Externally publishedYes


Dive into the research topics of 'Detectible mosaic truncating PPM1D mutations, age and breast cancer risk'. Together they form a unique fingerprint.

Cite this